fda ruling on compounded semaglutide Warns Against Using FDA Ban on Compounded GLP-1

Right to Information : Drug manufacturers and healthcare providers must provide adequate warnings about the potential side effects and risks associated with prescription medications

$149/month self-pay Lilly US obesity + diabetes market share: 60.1% Novo Nordisk Q1 2026: total revenue $10.8B, adjusted EPS $1.03

And if insurance companies see significant cost increases because of the popularity of a new drug, that cost gets passed along in higher premiumswhich already grow at a frustrating rate year-after-year

Theres also the possibility of insulin resistancethe bodys lowered ability to regulate blood sugarwhich comes with its own metabolic risk factors, like kidney disease and type 2 diabetes